{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:35Z","timestamp":1793225975752,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca, Gaithersburg, MD., USA","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of monalizumab (anti-NKG2A\/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1\/2 study of monalizumab and durvalumab evaluated safety, antitumor activity, and pharmacodynamics in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>\n                      Immunotherapy-na\u00efve patients aged \u226518 years with advanced disease, Eastern Cooperative Oncology Group performance status of 0\u20131, and 1\u20133 prior lines of systemic therapy in the recurrent\/metastatic setting were enrolled. In part 1 (dose escalation), patients received durvalumab 1500\u2009mg every 4 weeks (Q4W) with increasing doses of monalizumab Q2W\/Q4W (n=15). Dose expansion in part 1 included patients with cervical cancer (n=15; durvalumab 1500\u2009mg Q4W and monalizumab 750\u2009mg Q2W) or metastatic microsatellite stable (MSS)-colorectal cancer (CRC) (n=15; durvalumab 1500\u2009mg Q4W and monalizumab 750\u2009mg Q4W). In part 2 (dose expansion), patients with MSS-CRC (n=40), non-small cell lung cancer (NSCLC; n=20), MSS-endometrial cancer (n=40), or ovarian cancer (n=40) received durvalumab 1500\u2009mg Q4W and monalizumab 750\u2009mg Q2W. The primary endpoint was safety. Secondary endpoints included antitumor activity per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). Exploratory analyses included assessment of T-cell and natural killer (NK) cell activation and proliferation in peripheral blood and the tumor microenvironment (TME). The study enrolled 185 patients (part 1, 45; part 2, 140). No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. In part 2, the most common treatment-related adverse events were fatigue (12.1%), asthenia (9.3%), diarrhea (9.3%), pruritus (7.9%), and pyrexia (7.1%). In the expansion cohorts, response rates were 0% (cervical), 7.7% (MSS-CRC), 10% (NSCLC), 5.4% (ovarian), and 0% (MSS-endometrial). Sustained NK cell activation, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell proliferation, increased serum levels of CXCL10 (C-X-C motif chemokine ligand 10) and CXCL11, and increased tumor infiltration of CD8\n                      <jats:sup>+<\/jats:sup>\n                      and granzyme B\n                      <jats:sup>+<\/jats:sup>\n                      cells were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although efficacy was modest, monalizumab plus durvalumab was well tolerated and encouraging immune activation was observed in the peripheral blood and TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02671435\">NCT02671435<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-007340","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:45:22Z","timestamp":1706921122000},"page":"e007340","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":67,"title":["Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02671435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02643550","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04590963","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03822351","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05221840","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03794544","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":false,"given":"Sandip P","family":"Patel","sequence":"first","affiliation":[{"name":"University of California San Diego, Moores Cancer Center, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Wang","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"},{"name":"Johns Hopkins Medicine The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan E","family":"Standifer","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Research and Development, AstraZeneca, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kourtesis","sequence":"additional","affiliation":[{"name":"Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayukh","family":"Das","sequence":"additional","affiliation":[{"name":"Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R","family":"Diamond","sequence":"additional","affiliation":[{"name":"University of Colorado, Anschutz Medical Campus, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito A","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2025100313493606000_12.2.e007340.1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2021.11.016","article-title":"Natural killer cells and immune-Checkpoint inhibitor therapy: Current knowledge and new challenges","volume":"24","author":"Poggi","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"2025100313493606000_12.2.e007340.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor Microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"2025100313493606000_12.2.e007340.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025100313493606000_12.2.e007340.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2025100313493606000_12.2.e007340.5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of Pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100313493606000_12.2.e007340.6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.641428","article-title":"The tumor Microenvironment factors that promote resistance to immune Checkpoint blockade therapy","volume":"11","author":"Russell","year":"2021","journal-title":"Front Oncol"},{"key":"2025100313493606000_12.2.e007340.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0404"},{"key":"2025100313493606000_12.2.e007340.8","doi-asserted-by":"crossref","unstructured":"Chen Z , Yang Y , Liu LL , et al . n.d. Strategies to augment natural killer (NK) cell activity against solid tumors. Cancers;11:1040. doi:10.3390\/cancers11071040","DOI":"10.3390\/cancers11071040"},{"key":"2025100313493606000_12.2.e007340.9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"key":"2025100313493606000_12.2.e007340.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313493606000_12.2.e007340.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202065"},{"key":"2025100313493606000_12.2.e007340.12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ijc.33859","article-title":"Nkg2A is a late immune Checkpoint on Cd8 T cells and marks repeated stimulation and cell division","volume":"150","author":"Borst","year":"2022","journal-title":"Int J Cancer"},{"key":"2025100313493606000_12.2.e007340.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.014"},{"key":"2025100313493606000_12.2.e007340.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2108"},{"key":"2025100313493606000_12.2.e007340.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45816"},{"key":"2025100313493606000_12.2.e007340.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4179"},{"key":"2025100313493606000_12.2.e007340.17","first-page":"27","article-title":"Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract","volume":"35","author":"Aparicio-Pag\u00e9s","year":"1991","journal-title":"J Clin Lab Immunol"},{"key":"2025100313493606000_12.2.e007340.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100354108"},{"key":"2025100313493606000_12.2.e007340.19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3965"},{"key":"2025100313493606000_12.2.e007340.20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/bjc.2013.696","article-title":"Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients","volume":"110","author":"Zeestraten","year":"2014","journal-title":"Br J Cancer"},{"key":"2025100313493606000_12.2.e007340.21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2017.09.008","article-title":"The Prognostic benefit of tumour-infiltrating natural killer cells in endometrial cancer is dependent on concurrent overexpression of human Leucocyte antigen-E in the tumour Microenvironment","volume":"86","author":"Versluis","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100313493606000_12.2.e007340.22","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510382799"},{"key":"2025100313493606000_12.2.e007340.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100313493606000_12.2.e007340.24","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.4049\/jimmunol.160.4.1618","article-title":"Participation of the Cd94 receptor complex in Costimulation of human natural killer cells","volume":"160","author":"Voss","year":"1998","journal-title":"J Immunol"},{"key":"2025100313493606000_12.2.e007340.25","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.4.397"},{"key":"2025100313493606000_12.2.e007340.26","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00262-020-02833-z","article-title":"Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by Durvalumab in advanced NSCLC patients","volume":"70","author":"Naidus","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100313493606000_12.2.e007340.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114"},{"key":"2025100313493606000_12.2.e007340.28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.23922\/jarc.2020-064","article-title":"Immunotherapy in colorectal cancer: current and future strategies","volume":"5","author":"Ooki","year":"2021","journal-title":"J Anus Rectum Colon"},{"key":"2025100313493606000_12.2.e007340.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.028"},{"key":"2025100313493606000_12.2.e007340.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049135","article-title":"Natural killer cells are characterized by the Concomitantly increased interferon-gamma and cytotoxicity in acute resolved hepatitis B patients","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS ONE"},{"key":"2025100313493606000_12.2.e007340.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"2025100313493606000_12.2.e007340.32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1161048","article-title":"The role of Immunotherapy in Microsatellites stable metastatic colorectal cancer: state of the art and future perspectives","volume":"13","author":"Gandini","year":"2023","journal-title":"Front Oncol"},{"key":"2025100313493606000_12.2.e007340.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.10.142","article-title":"Monalizumab, Cetuximab and Durvalumab in first line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN): a phase 2 trial","volume":"32","author":"Colevas","year":"2021","journal-title":"Annals of Oncology"},{"key":"2025100313493606000_12.2.e007340.34","unstructured":"pharma I . Innate pharma provides update on Astrazeneca-sponsored INTERLINK-1 phase 3 study. 2022."},{"key":"2025100313493606000_12.2.e007340.35","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of Durvalumab alone or in combination with Oleclumab or Monalizumab in patients with Unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12_Supplement","key":"2025100313493606000_12.2.e007340.36","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT011","article-title":"Neocoast: open-label, randomized, phase 2, multidrug platform study of Neoadjuvant Durvalumab alone or combined with novel agents in patients (Pts) with Resectable, early-stage non-small cell lung cancer (NSCLC)","volume":"82","author":"Cascone","year":"2022","journal-title":"Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:49:47Z","timestamp":1759524587000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,2]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/jitc-2023-007340"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007340","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}